LGND
Ligand Pharmaceuticals Incorporated · NASDAQ
- Market cap
- $6.18B
Ligand Pharmaceuticals Incorporated (LGND) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. In the last 30 days Quantisnow tracked 10 wire items for LGND, including 4 insider trades, 3 SEC filings and 2 press releases and news items. The most recent was published Nov 12, 2026.
LGND rankings
Financial highlights
Full financials- Revenue, TTM
- $253.83M
- Revenue growth
- +1.0%
- Net income, TTM
- $51.46M
- Net margin
- 20.3%
- Free cash flow, TTM
- $90.63M
- Cash
- $55.96M
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks61+200%
2026-05-242026-11-15
Mix2490d
- Insider8(33%)
- Other6(25%)
- SEC Filings6(25%)
- Earnings2(8%)
- M&A1(4%)
- Analyst1(4%)
Activity · 52 weeks12176 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Latest news
25 items- INSIDERDirector Aryeh Jason sold $960,141 worth of shares (3,000 units at $320.05), decreasing direct ownership by 3% to 105,476 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECSEC Form 144 filed by Ligand Pharmaceuticals Incorporated144 - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
- INSIDERDirector Aryeh Jason sold $90,237 worth of shares (282 units at $319.99), decreasing direct ownership by 0.26% to 108,476 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERCLO & Secretary Reardon Andrew exercised 5,000 shares at a strike of $52.27 and sold $1,566,094 worth of shares (5,000 units at $313.22) as part of a pre-agreed trading plan (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERDirector Aryeh Jason sold $676,158 worth of shares (2,111 units at $320.30), decreasing direct ownership by 2% to 108,758 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECSEC Form 10-Q filed by Ligand Pharmaceuticals Incorporated10-Q - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- SECSEC Form 8-K filed by Ligand Pharmaceuticals Incorporated8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Reports Third Quarter 2026 Financial ResultsThird-quarter royalty revenue up 51% year-over-year to $70.3 million Raises Full-Year 2026 Adjusted Diluted EPS Guidance to $9.50 to $9.75, from $9.00 to $9.501; Reaffirms Revenue Guidance Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "Ligand delivered another strong quarter, with royalty revenue growing
- PRLigand to Participate in November Investor ConferencesJUPITER, Fla., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its senior management team will participate in the following upcoming investor conferences: UBS Global Healthcare Conference. Management will participate in one-on-one meetings with investors on November 9, 2026 in Palm Beach Gardens.Stifel 2026 Healthcare Conference. Management will participate in a fireside chat on November 10, 2026 at 10:40 a.m. ET in New York.Miami Biotech Collective Summit 2026. Management will participate in one-on-one meetings with investors on November 30, 2026 in Miami. Investors interested in arranging one-on-one meetings should contact their
- PRLigand to Host Investor Day on December 8, 2026JUPITER, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its annual Investor Day will take place on Tuesday, December 8, 2026 from 10:30 a.m. to 12:00 p.m. ET at the Harvard Club of New York City at 35 West 44th Street, New York, NY 10036. The event will include presentations from Ligand CEO Todd Davis, CFO Tavo Espinoza and other members of the Ligand senior management team. Presentations will highlight the company’s strategy, investment activity, royalty portfolio, and long-term financial outlook. Wes Kaupinen, Founder and CEO of Palvella Therapeutics, a Ligand partner, will be a guest speaker at the event and discuss the pr
- PRLigand to Report Third Quarter 2026 Financial Results on October 29, 2026JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, October 29, 2026 Time:8:30 a.m. Eastern time Conference Call:United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in Numbers Meeting ID: 708822080 Webcast:Live and replay webcasts of the call are available here. About LigandLigand is a le
- INSIDERCLO & Secretary Reardon Andrew sold $1,520,346 worth of shares (5,000 units at $304.07) as part of a pre-agreed trading plan (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- ANALYSTBarclays initiated coverage on Ligand Pharma with a new price targetBarclays initiated coverage of Ligand Pharma with a rating of Overweight and set a new price target of $345.00
- INSIDERDirector Zimmermann Martine covered exercise/tax liability with 115 shares, decreasing direct ownership by 3% to 3,782 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECSEC Form 8-K filed by Ligand Pharmaceuticals Incorporated8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 MillionJUPITER, Fla., Sept. 24, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it has entered into a financing agreement with AvenCell Therapeutics, Inc., a clinical-stage cell therapy company developing controllable, allogeneic CAR-T therapies for patients with cancer, for up to $47 million. The investment will help advance AvenCell’s pipeline, including AVC-201 for the treatment of relapsed/refractory acute myeloid leukemia (AML) and AVC-203 for the treatment of B-cell malignancies. Under the terms of the agreement, Ligand has committed up to $41 million in exchange for a mid single-digit to low double-digit royalty on worldwide annual net sales
- PRSydnexis Announces Royalty Agreement with Ligand for Ryjunea®$23 million upfront payment immediately monetizes future royalties associated with Ryjunea in Europe, the Middle East, and Africa Capital further strengthens Sydnexis’ balance sheet as Company continues to advance SYD-101 through U.S. regulatory process and prepares for potential commercialization in 2027 Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced an agreement with Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) to sell its royalty rights associated with net sales of Ryjunea® in Europe, the Middle East, and Africa (EMEA). Under the terms of the agreement, Ligand
- PRPrimrose Bio® Raises Significant Growth Capital Investment Led by Signet Healthcare PartnersSAN DIEGO, Sept. 22, 2026 /PRNewswire/ -- Primrose Bio, Inc. ("Primrose"), a provider of production solutions for next-generation biologics, today announced the closing of a financing round led by new investor Signet Healthcare Partners ("Signet"), with significant participation from existing investors 1315 Capital, Ligand Pharmaceuticals Incorporated (NASDAQ:LGND), LDV Partners, and Agent Capital. In conjunction with the financing, James Gale, Founding Partner and Managing Director of Signet, has joined Primrose's Board of Directors. The proceeds will help Primrose continue to expand the reach and capabilities of its different
- SECLigand Pharmaceuticals Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand Acquires Royalty and Milestone Interest in Santen’s Ryjunea® from Sydnexis for $23 MillionRyjunea is the first and only pharmacologic treatment approved by the European Commission and UK MHRA to slow myopia progression in pediatric patients Ligand will receive a tiered low-double-digit to high-teens royalty on Ryjunea net sales in Europe, the Middle East, and Africa JUPITER, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced it has acquired an ascending tiered royalty interest in Santen Pharmaceutical Co., Ltd.’s ("Santen") Ryjunea® from Sydnexis, Inc. ("Sydnexis") for a $23 million upfront payment. Ryjunea is a once-nightly, low-dose atropine eye drop designed to slow progression of myopia (commonly known as nearsighte
- INSIDERDirector Zimmermann Martine sold $342,000 worth of shares (1,200 units at $285.00), decreasing direct ownership by 24% to 3,897 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- INSIDERCLO & Secretary Reardon Andrew sold $1,430,434 worth of shares (5,000 units at $286.09) as part of a pre-agreed trading plan, decreasing direct ownership by 12% to 36,514 units (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
- SECAmendment: Ligand Pharmaceuticals Incorporated filed SEC Form 8-K: Financial Statements and Exhibits8-K/A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
- PRLigand to Participate in September Investor ConferencesJUPITER, Fla., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced its senior management team will participate in the following upcoming investor conferences: Wells Fargo Healthcare Conference 2026 (Boston): Management will participate in a fireside chat at 12:45 p.m. ET on September 8, 2026.Citi 2026 Biopharma Back to School Conference (New York): Management will participate in a fireside chat at 9:20 a.m. ET on September 10, 2026.H.C. Wainwright 28th Annual Global Investment Conference (New York): Management will present on September 14, 2026 at 10:00 a.m. ET. Ligand management is scheduled to host one-on-one meetings with investors and a
- INSIDERChief Financial Officer Espinoza Octavio exercised 31,641 shares at a strike of $56.91 and sold $9,241,229 worth of shares (31,641 units at $292.06) as part of a pre-agreed trading plan (SEC Form 4)4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
LGND FAQ
10 questionsWhat does Ligand Pharmaceuticals Incorporated do?
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. The company's commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for the treatment of osteoporosis; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of PPD; Noxafil-IV, a captisol-enabled...What is the latest news on LGND?
In the last 30 days Quantisnow tracked 10 wire items for LGND: 4 insider trades, 3 SEC filings, 2 press releases and news items and 1 earnings update. The most recent was published on November 12, 2026.What is LGND revenue?
Ligand Pharmaceuticals Incorporated (LGND) reported $253.83M of revenue for the twelve months ended Sep 30, 2026. That is up 1.0% from the year before. Revenue for fiscal 2025 was $268.09M.Is LGND profitable?
Yes. Ligand Pharmaceuticals Incorporated earned $51.46M in net income for the twelve months ended Sep 30, 2026, a net margin of 20.3%.How much cash and debt does LGND have?
Ligand Pharmaceuticals Incorporated reported $55.96M in cash and cash equivalents and $1.13B of debt on its most recent balance sheet in SEC filings.Where does LGND stock trade?
Ligand Pharmaceuticals Incorporated (LGND) is listed on NASDAQ.What sector and industry is LGND in?
Ligand Pharmaceuticals Incorporated operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about LGND?
Ligand Pharmaceuticals Incorporated has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $345.00 price target on 2026-09-25. Recent price targets range from $130.00 to $387.00.What companies are similar to LGND?
Notable peers in the same industry include MRK (Merck & Company Inc.), NVO (Novo Nordisk A/S), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABT (Abbott Laboratories). Compare LGND side-by-side with any of them on Quantisnow.How can I track LGND on Quantisnow?
Quantisnow aggregates Ligand Pharmaceuticals Incorporated's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow LGND to receive live email and push alerts on every new disclosure.